Par Drugs & Chemicals Ltd Surges 56.38% in Volatile Week: Key Drivers and Market Reaction

31 August: Strong Rally Begins Amid Market Weakness

Par Drugs & Chemicals Ltd opened the week on a robust note, surging 17.10% to close at Rs.117.35 despite the Sensex falling 0.48% to 36,615.95. This sharp gain marked a significant shift in investor sentiment, signalling renewed interest in the stock. The volume of 3.26 lakh shares indicated healthy participation, supporting the price move. The rally coincided with a broader market sell-off, highlighting the stock’s relative strength.

1 September: Valuation Shift Amid Continued Price Surge

The momentum accelerated on 1 September as Par Drugs gained 19.81% to Rs.140.60, nearly touching its 52-week high of Rs.142.43. This price appreciation was accompanied by a notable shift in valuation metrics. The company’s price-to-earnings ratio rose to 9.97, and the price-to-book value increased to 1.29, prompting a reclassification from an attractive to a fair valuation grade as of 26 August 2026. Despite the strong rally, the stock remained reasonably valued compared to sector peers, many of which trade at significantly higher multiples.

Meanwhile, the Sensex declined 0.30% to 36,506.61, underscoring Par Drugs’ outperformance. The volume surged to over 6.19 lakh shares, reflecting growing investor interest amid the valuation recalibration.

2 September: Peak Momentum with 19.67% Gain

On 2 September, Par Drugs extended its rally, climbing 19.67% to a weekly high of Rs.168.25. This represented a near 68% gain from the previous Friday’s close of Rs.100.21. The surge was supported by heavy trading volume of 15.08 lakh shares, indicating strong conviction among buyers. The Sensex continued its downward trend, falling 0.44% to 36,344.55, further highlighting the stock’s divergence from broader market sentiment.

At this stage, the company’s Mojo Score stood at 68.0 with a Hold rating, reflecting a cautious stance despite the impressive price gains. The valuation shift to fair suggested that while the stock had momentum, the margin of safety had narrowed.

3 September: Profit-Taking Triggers Mild Pullback

After three consecutive days of strong gains, the stock experienced a modest correction on 3 September, declining 1.96% to close at Rs.164.95. The volume of 7.26 lakh shares remained elevated, with delivery volumes rising by 69.42% compared to the five-day average, suggesting investors were increasingly holding shares rather than engaging in intraday trading.

The Sensex fell marginally by 0.08% to 36,315.81, indicating a broadly cautious market environment. Despite the pullback, Par Drugs remained well above key moving averages, signalling that the longer-term uptrend was intact.

4 September: Sharp Sell-Off Hits Lower Circuit Amid Heavy Selling

The week ended with a dramatic reversal as Par Drugs plunged 5.00% to Rs.156.71, hitting the lower circuit limit. The stock opened near its intraday high of Rs.168.00 but succumbed to intense selling pressure, closing at the day’s low. The total traded volume was thin at just 10,607 shares, reflecting limited liquidity typical of micro-cap stocks.

This sharp decline contrasted with the broader market, where the Sensex gained 0.19% to 36,385.87 and the Chemicals & Petrochemicals sector rose 0.41%. The sell-off was driven by panic selling and unfilled supply, exacerbated by the downgrade from a Buy to Hold rating issued on 26 August 2026. The stock’s micro-cap status and valuation concerns likely contributed to the heightened volatility.

Key Takeaways

Strong Outperformance Amid Market Weakness: Par Drugs & Chemicals Ltd’s 56.38% weekly gain starkly contrasts with the Sensex’s 1.11% decline, underscoring the stock’s exceptional momentum in a challenging market environment.

Valuation Shift Reflects Maturing Investment Case: The upgrade from attractive to fair valuation grade signals that the stock’s rapid price appreciation has narrowed the margin of safety, with P/E at 9.97 and P/BV at 1.29 now reflecting a more balanced outlook.

Volatility and Liquidity Risks: The sharp fall to the lower circuit on 4 September highlights the micro-cap’s susceptibility to sudden swings and limited liquidity, factors that investors must consider carefully.

Hold Rating and Mojo Score 68.0: The downgrade from Buy to Hold indicates a more cautious analyst stance, suggesting that while the stock has strong short-term returns, risks remain elevated.

Sector Resilience but Stock-Specific Pressure: Despite the Chemicals & Petrochemicals sector’s modest gains on the last day, Par Drugs underperformed sharply, indicating company-specific factors driving the sell-off.

Conclusion

Par Drugs & Chemicals Ltd’s week was characterised by extraordinary gains followed by a sharp correction, reflecting a volatile trading environment typical for micro-cap stocks. The stock’s strong outperformance against the Sensex and sector peers was underpinned by improved valuation metrics and solid profitability, yet the downgrade to a Hold rating and the lower circuit hit underscore the risks of rapid price swings and liquidity constraints. Investors should approach this stock with caution, monitoring upcoming corporate developments and sector trends closely before making further commitments.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today